Roganovic Jelena, Virgone Calogero, Ben-Ami Tal, Reguerre Yves, Ferrari Andrea, Orbach Daniel, Godzinski Jan, Bisogno Gianni, Farinha Nuno Jorge, Krawczyk Malgorzata, Schneider Dominik T, Brecht Ines B, Bien Ewa
Department of Hematology and Oncology, Children's Hospital Zagreb, Zagreb, Croatia.
Pediatric Surgery Division, University of Padua, University Hospital of Padua, Via Giustiniani 3, 35128, Padua, Italy.
Clin Transl Oncol. 2025 Apr;27(4):1779-1788. doi: 10.1007/s12094-024-03674-3. Epub 2024 Sep 3.
Within the Paediatric Rare Tumours Network-European Registry (PARTNER) project, we aimed to evaluate the situation on the registration and management of paediatric patients affected by very rare tumours (VRT) in the European low health expenditure average rates (LHEAR) countries.
A survey regarding infrastructure, organisation, and clinical decision-making information on VRT was designed. This survey was distributed to the representatives of LHEAR countries involved in the activities of the PARTNER Work Package 7.
Eighteen answers from 17 countries were collected regarding the national organisation, methods of registration of VRT cases, the availability of medical experts in VRT, the access to updated diagnostic and therapeutic procedures (such as proton therapy, immunotherapy and, targeted therapies), and research on paediatric VRT. A high variability in the registration and management of patients with VRT has been observed with additional wide inequalities in pathology review, uniformity of clinical decisions, availability of selected procedures, and diagnostic and research tools.
In the majority of LHEAR countries, no clinical or research structures have been implemented for children and adolescents with VRT. Therefore, VRT still have an orphan status in these countries. These significant differences on the technology access and use between European regions need to be addressed.
在儿科罕见肿瘤网络 - 欧洲登记处(PARTNER)项目中,我们旨在评估欧洲低卫生支出平均率(LHEAR)国家中受极罕见肿瘤(VRT)影响的儿科患者的登记和管理情况。
设计了一项关于VRT的基础设施、组织和临床决策信息的调查。该调查分发给参与PARTNER工作包7活动的LHEAR国家的代表。
收集到了来自17个国家的18份回复,内容涉及国家组织、VRT病例的登记方法、VRT医学专家的可及性、获得最新诊断和治疗程序(如质子治疗、免疫治疗和靶向治疗)的情况以及儿科VRT研究。观察到VRT患者的登记和管理存在很大差异,在病理审查、临床决策的一致性、选定程序的可及性以及诊断和研究工具方面还存在广泛的不平等。
在大多数LHEAR国家,尚未为患有VRT的儿童和青少年建立临床或研究结构。因此,VRT在这些国家仍处于孤儿地位。欧洲各地区在技术获取和使用方面的这些重大差异需要得到解决。